Valuation: Alkermes plc

Market Cap 825.56Cr 707.42Cr 662.87Cr 605.49Cr 1.14TCr 79TCr 1.15TCr 7.82TCr 3.04TCr 40TCr 3.1TCr 3.03TCr 1,31500Cr P/E 2026 *
-96.5x
P/E 2027 * 67.7x
Enterprise Value 899.95Cr 771.17Cr 722.6Cr 660.05Cr 1.25TCr 86TCr 1.26TCr 8.52TCr 3.32TCr 43TCr 3.38TCr 3.31TCr 1,43400Cr EV / Sales 2026 *
4.93x
EV / Sales 2027 * 4.59x
Free-Float
89.45%
Yield 2026 *
-
Yield 2027 * -
1 day+0.70%
1 week-0.55%
Current month+0.45%
1 month-6.96%
3 months+33.72%
6 months+58.54%
Current year+75.88%
1 week 47.33
Extreme 47.33
49.86
1 month 47.33
Extreme 47.33
53.84
Current year 27
Extreme 27
55.67
1 year 25.16
Extreme 25.165
55.67
3 years 22.01
Extreme 22.01
55.67
5 years 21.24
Extreme 21.24
55.67
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 53 01/08/2026
Director of Finance/CFO 53 15/09/2025
Chief Tech/Sci/R&D Officer 58 30/05/2017
Director TitleAgeSince
Chairman 64 01/09/2011
Director/Board Member 74 26/05/2016
Director/Board Member 63 30/03/2018
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Sell

Executive/Senior Manager

-7,576 0.0045%
05/08/26 Free

Chief Executive Officer

2,17,534 0.1297%
03/08/26 Sell

Compliance Officer

-2,034 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+0.70%-0.55%+69.69%+81.12% 825.56Cr
-0.35%+2.31%+2.49%+24.63% 5.17TCr
-0.09%-2.14%+492.60%+537.84% 4.53TCr
-0.32%+8.08%+37.97%+18.45% 4.27TCr
+1.18%+1.96%+21.95%+89.69% 4.28TCr
-2.27%-3.02%+14.22%+51.50% 3.29TCr
-0.96%+4.03%+31.55%+136.34% 1.71TCr
+0.41%+1.66% - - 1.66TCr
+0.43%+5.29%+13.52%+31.36% 1.5TCr
-0.31%+6.61%+81.37%+48.53% 1.42TCr
Average -0.17%+2.62%+85.04%+113.27% 2.87TCr
Weighted average by Cap. -0.24%+2.65%+103.54%+133.83%

Financials

2026 *2027 *
Net sales 182.49Cr 156.38Cr 146.53Cr 133.84Cr 252.59Cr 17TCr 255.09Cr 1.73TCr 672.84Cr 8.78TCr 685.22Cr 670.29Cr 29TCr 194.48Cr 166.65Cr 156.16Cr 142.64Cr 269.2Cr 19TCr 271.85Cr 1.84TCr 717.07Cr 9.35TCr 730.25Cr 714.34Cr 31TCr
Net income -8.99Cr -7.71Cr -7.22Cr -6.59Cr -12Cr -857.24Cr -13Cr -85Cr -33Cr -432.5Cr -34Cr -33Cr -1.43TCr 12Cr 10Cr 9.66Cr 8.82Cr 17Cr 1.15TCr 17Cr 113.92Cr 44Cr 578.56Cr 45Cr 44Cr 1.92TCr
Net Debt 74Cr 64Cr 60Cr 55Cr 102.97Cr 7.09TCr 103.98Cr 704.57Cr 274.28Cr 3.58TCr 279.33Cr 273.24Cr 12TCr 67Cr 57Cr 54Cr 49Cr 93Cr 6.39TCr 94Cr 634.49Cr 247Cr 3.22TCr 251.54Cr 246.06Cr 11TCr
Logo Alkermes plc
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Employees
2,050
Date Price Change Volume
25/26/25 $49.21 +0.70% 11,27,442
24/26/24 $48.87 +1.12% 12,96,669
21/26/21 $48.33 +0.65% 9,39,640
20/26/20 $48.02 -4.30% 16,35,207
19/26/19 $50.18 +1.41% 15,44,219
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
49.21USD
Average target price
56.00USD
Spread / Average Target
+13.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALKS Stock